Briya Extends Real-World Data Reach and Sharpens AI Infrastructure Focus Amid Shifting FDA Standards

Briya spent the week underscoring its role as a real-world data and healthtech infrastructure provider, emphasizing that AI progress in healthcare is increasingly constrained by data quality and interoperability rather than algorithms. The company highlighted access to more than 120 million AI-ready patient journeys across multiple countries, aimed at supporting drug development, outcomes research, and large-scale evidence generation.

Briya is aligning its platform with evolving U.S. FDA expectations that allow a single well-controlled trial supplemented by confirmatory real-world evidence, stressing that the key bottleneck is processing and standardizing complex clinical data. Executives including Co-Founder and CEO David Lazerson and Prof. Fabio Lievano argued that integrating disparate data sources into complete patient journeys can help biopharma sponsors meet regulatory-grade evidence standards.

The company also spotlighted a retrospective real-world data study on GLP-1 use for obesity in patients with mental health conditions, to be presented at ISPOR U.S. 2026. By focusing on treatment patterns, adherence, and patient stratification, Briya aims to deepen its ties with payers, providers, and life-science partners in high-growth therapeutic areas such as obesity and metabolic disease.

Across multiple LinkedIn posts, Briya framed augmented intelligence as a strategic response to tightening funding conditions in biotech, positioning data-driven decision support as a way to reduce uncertainty from early research through clinical development. Participation in industry events such as HLTH Europe, the InterSystems READY summit, and AI4Purpose further embeds the company within enterprise health IT and interoperability ecosystems.

Collectively, these developments reinforce Briya’s positioning at the intersection of AI-ready data infrastructure, real-world evidence, and evolving regulatory requirements, which could enhance its long-term relevance to biopharma, payers, and healthcare systems. While financial metrics remain undisclosed, the company’s focus on scalable, compliant data capabilities and thought leadership suggests a strategic push to cement its role as core infrastructure for AI-enabled healthcare and research.